S-1: Catheter Precision Eyes $5 Million Capital Raise Through Public Offering

Catheter Precision, Inc. announces a firm commitment public offering of common stock and pre-funded warrants to raise approximately $5 million for operations, clinical trials, and debt repayment.

Summary

• Catheter Precision, Inc. has filed a Form S-1 registration statement for a proposed public offering.
• The offering includes shares of common stock and pre-funded warrants, with an aggregate target of approximately $5 million.
• The company intends to use the net proceeds to support operations, including clinical trials, working capital, and repayment of interim financing.
• Certain existing stockholders have indicated an interest in purchasing up to $[ ] of common stock in the offering.
• The offering also includes the issuance of underwriter warrants to purchase 6% of the total shares sold.
• The company's stock is listed on NYSE American under the symbol VTAK.
• A reverse stock split and reduction in authorized shares are subject to stockholder approval at the July 3, 2024 annual meeting.

Sentiment

Score: 6

Explanation: The document is neutral. While it announces a capital raise, it also highlights risks and uncertainties associated with the company's financial position and the offering itself.

Positives

• The capital raise will provide funding for ongoing operations, clinical trials, and working capital.
• Repayment of interim financing from the CEO will improve the company's financial position.
• Existing stockholders' interest in purchasing shares demonstrates confidence in the company.
• The company has two primary products, VIVO and LockeT, with potential for growth in the cardiac electrophysiology market.
• The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe.
• LockeT is a sterile, Class I product that we registered with the FDA in February 2023, at which time we began initial shipments for product evaluations.
• During the second quarter of 2024, the product received its first approval for future use by a U.S. medical center, which has submitted several purchase orders to date.

Negatives

• The offering will result in immediate and substantial dilution for new investors.
• The company has broad discretion over the use of proceeds, which may not yield a favorable return.
• There is no established public trading market for the pre-funded warrants.
• The company has a history of losses and may never achieve profitability.
• The company identified material weaknesses in its internal control over financial reporting.
• The company will not be able to reach profitability unless it is able to achieve its product expansion and growth goals; its VIVO launch plans require significant investment in infrastructure and sales representatives.
• Royalty agreements with respect to LockeT, the surgical vessel closing pressure device, will reduce any future profits from this product.

Risks

• The company may not use the proceeds effectively.
• Investors will experience immediate and substantial dilution.
• Future issuances of equity securities may negatively impact the trading price of the common stock.
• There is no public market for the pre-funded warrants.
• The company may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing Shares or other securities in the future could have rights superior to existing stockholders.
• The company will be required to raise additional funds to finance its operations and continue as a going concern; it may not be able to do so when necessary, and/or the terms of any financings may not be advantageous to it.
• The company may incur material losses and costs as a result of product liability claims that may be brought against it and recalls, which may adversely affect its results of operations and financial condition.
• The company may be unable to compete successfully with companies in its highly competitive industry, many of whom have substantially greater resources than it does.
• The company's revenues may depend on its customers receipt of adequate reimbursement from private insurers and government sponsored healthcare programs.
• The company is subject to pervasive and continuing regulation by the FDA and other regulatory agencies. Its products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm its reputation, and adversely affect its business.

Future Outlook

The company aims to establish VIVO and LockeT as integral tools used by cardiac electrophysiologists during and following ablation treatment of ventricular arrhythmias, by reducing procedure time and patient complications and increasing procedural efficiencies and success.

Industry Context

The EP market is estimated to be $15.1 billion by 2028 (CAGR of 13.0%). Population growth, increasing rates of heart disease and the rising cost of healthcare are driving growth in the EP markets. The catheter ablation market was larger than $3.5 billion in 2022 and is estimated to grow to $14.5 billion by 2032 (13.5% CAGR).

Comparison to Industry Standards

• The EP market includes large medical device companies such as Medtronic, Plc., Abbott Laboratories, Biosense-Webster (J&J) and Boston Scientific Corp.
• LockeTs direct competitors include Abbotts Perclose device, Haemonetics VASCADE device and Inari Medicals FlowStasis device.
• A recent peer-reviewed multicenter study sponsored by Biosense Webster, entitled Paroxysmal AF Catheter Ablation with a Contact Force Sensing Catheter published in 2014 found that catheter ablation success rates can be as high as 80% when the physician is able to maintain stable contact force within investigator selected working ranges.
• In the TOCCASTAR study, 85.5% of ablation procedure patients were free of atrial fibrillation at one year after the procedure when optimal catheter tip contact force was maintained, versus only 67.7% when non-optimal contact force was achieved.

Related Party Transactions

• The company borrowed $500,000 from its CEO on May 30, 2024, to fund short-term liquidity needs, which it expects to repay with proceeds from this offering.

Stakeholder Impact

• New investors will experience immediate dilution.
• Existing stockholders may benefit from the company's increased financial stability.
• The capital raise will support the company's operations and product development, potentially benefiting patients and healthcare providers.

Next Steps

• Stockholder vote on reverse stock split and reduction in authorized shares on July 3, 2024.
• Completion of Phase II clinical studies for LockeT anticipated by the end of Q3 2024.
• Anticipated CE Mark approval for LockeT in the second half of 2024.
• Completion of Phase III clinical studies for LockeT anticipated in early 2025.

Key Dates

Keywords

public offering, pre-funded warrants, common stock, capital raise, Catheter Precision, VIVO System, LockeT, electrophysiology, clinical trials, medical devices